Paula Pohlmann, Professor at The University of Texas M.D. Anderson Cancer Center, shared a post on LinkedIn:
“More results presented at the 2025 SABCS:
Transcriptomic profiling reveals distinct immune landscapes in rare breast cancer subtypes. This work was led by Elyse Lopez and Bora Lim.
Researchers from MD Anderson Cancer Center [Department of Breast Medical Oncology and Inflammatory Breast Cancer Team] in collaboration with BostonGene presented a poster highlighting immune-related differences in inflammatory breast cancer (IBC) and metaplastic breast cancer (MpBC).
Using AI-driven analysis of 341 breast cancer samples, the team found:
- IBC: Upregulated JAK/STAT signaling and increased effector immune cells (CD4 T cells, B cells, NK cells, neutrophils)
- MpBC: EMT-enriched profile with reduced CD8 T-cell infiltration and elevated M2 macrophages; however, the MpBC cohort was small, limiting definitive conclusions.
These findings suggest IBC patients may benefit from immune‑based interventions. The study underscores the importance of tailored approaches for rare subtypes and calls for further validation.”
More posts featuring Paula Pohlmann.